Related Experiment Video

Updated: Feb 21, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.4K

LncRNA UCA1 in anti-cancer drug resistance

Haohao Wang1,2, Zhonghai Guan1, Kuifeng He1,2

  • 1Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.

Oncotarget
|October 4, 2017
PubMed

Insights

The long non-coding RNA urothelial carcinoma associated 1 (UCA1) promotes resistance to multiple anti-cancer drugs. Reducing UCA1 levels can restore drug sensitivity, highlighting its potential as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) play critical roles in various cellular processes, including cancer development.
  • Urothelial carcinoma associated 1 (UCA1) is a lncRNA implicated in numerous cancers.
  • Drug resistance remains a significant challenge in cancer therapy, necessitating the identification of novel therapeutic targets.

Purpose of the Study:

  • To review the role of lncRNA UCA1 in the development of anti-cancer drug resistance.
  • To discuss the potential clinical applications of UCA1 as a biomarker and therapeutic target.

Main Methods:

  • Literature review of studies investigating the function of UCA1 in cancer.
  • Analysis of the correlation between UCA1 expression and resistance to various chemotherapeutics.
  • Examination of the effects of UCA1 knockdown on drug sensitivity.

Main Results:

  • Overexpression of UCA1 is associated with resistance to a wide range of anti-cancer drugs, including cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib, and EGFR-TKIs.
  • Knockdown of UCA1 has been shown to restore sensitivity to these chemotherapeutics.
  • UCA1's role in drug resistance is conserved across various cancer types.

Conclusions:

  • lncRNA UCA1 is a key regulator of anti-cancer drug resistance.
  • UCA1 holds significant potential as a diagnostic and prognostic biomarker for cancer patients.
  • Targeting UCA1 presents a promising therapeutic strategy to overcome drug resistance in malignant tumors.
Keywords:
UCA1cancerchemoresistancelong non-coding RNA

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K